Not So Different: A Podcast From The Center For Biosimilars

S5 Ep2: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market

Informações:

Sinopsis

To learn more about the hype regarding adalimumab biosimilars in the US, click here. To see which biosimilars have been approved by the FDA, click here. To read more on PBMs and their influence on biosimilar uptake, click here. To read Manolis’ 2016 paper, click here.